{"entity":{"id":"paper-chapuis-cd8-central-memory-melanoma-pnas-2012","kind":"paper","name":"Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype","aka":[],"tldr":"In eleven people with advanced melanoma given cyclophosphamide and then their own melanoma-targeting T cells, one had a complete remission lasting over three years, and the cells that survived changed into long-lived memory cells.","summary":"Eleven patients with refractory, progressive metastatic melanoma received cyclophosphamide alone as conditioning before infusion of blood-derived, antigen-specific CD8+ CTL clones, followed by low-dose or high-dose IL-2 (PNAS 2012). The infused clones had an effector memory phenotype, and those that persisted long term acquired central memory qualities in vivo (PNAS 2012).","asOf":"2026-11-05","links":[{"label":"DOI 10.1073/pnas.1113748109","url":"https://doi.org/10.1073/pnas.1113748109"},{"label":"PubMed 22393002","url":"https://pubmed.ncbi.nlm.nih.gov/22393002/"}],"tags":[],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["cyclophosphamide","aldesleukin"],"companies":[],"institutions":["fred-hutch"],"pathways":[],"terms":["endogenous-t-cell-therapy"],"trials":[],"people":["cassian-yee"],"bottlenecks":[],"keyPapers":[],"journals":["pnas"],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo agent (Claude Opus 5.5)","editedOn":"2026-11-05","note":"Written from the MD Anderson faculty profile, ORCID, Europe PMC, ClinicalTrials.gov v2, SEC EDGAR and each organisation's own site, read on 5 November 2026."},"journal":"Proceedings of the National Academy of Sciences of the United States of America","year":2012,"doi":"10.1073/pnas.1113748109","pmid":"22393002","authors":"Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee C.","paperType":"translational","findings":["No life-threatening toxicities occurred with low-dose IL-2.","Five of 10 evaluable patients had stable disease at 8 weeks, and 1 of 11 had a complete remission continuing for longer than 3 years.","On-target autoimmune events with early skin rashes were seen in patients with stable disease or complete remission at 4 weeks or longer."],"whatItMeans":"Infused T-cell clones can convert to a central memory type in the body, which may underlie lasting benefit.","caveats":["Eleven patients and no control group."],"participants":11},"route":"/key-papers/paper-chapuis-cd8-central-memory-melanoma-pnas-2012/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"aldesleukin","kind":"drug","name":"Aldesleukin (high-dose IL-2)","route":"/drugs/aldesleukin/"},{"id":"cyclophosphamide","kind":"drug","name":"Cyclophosphamide","route":"/drugs/cyclophosphamide/"}],"institution":[{"id":"fred-hutch","kind":"institution","name":"Fred Hutchinson Cancer Center","route":"/institutions/fred-hutch/"}],"term":[{"id":"endogenous-t-cell-therapy","kind":"term","name":"Endogenous T-cell therapy","route":"/terms/endogenous-t-cell-therapy/"}],"person":[{"id":"cassian-yee","kind":"person","name":"Cassian Yee","route":"/people/cassian-yee/"}],"journal":[{"id":"pnas","kind":"journal","name":"Proceedings of the National Academy of Sciences","route":"/journals/pnas/"}]}}